SEC INSIDER TRANSACTIONS

RESMED INC (RMD) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

RMD · RESMED INC

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 20 filings · fetched 2026-11-13T19:57:04Z

Recent reported activity

0purchase rows on this page

5sale rows on this page

36matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-11-11Filed 2026-11-13	Rider Michael JOfficer · Global General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. F2 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. F3 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. F4 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. F5 Includes 41.7624 shares of Resmed stock purchased on Oct 30, 2026 through the Resmed Employee Stock Purchase Plan. References: F4, F5	F WithholdingResMed Common Stock · Non-derivative	172.993D	234.11	Direct	Form 4 ↗0000943819-26-000096
2026-11-11Filed 2026-11-13	Rider Michael JOfficer · Global General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. F2 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. F3 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. F4 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. F5 Includes 41.7624 shares of Resmed stock purchased on Oct 30, 2026 through the Resmed Employee Stock Purchase Plan. References: F3	F WithholdingResMed Common Stock · Non-derivative	724.414D	234.11	Direct	Form 4 ↗0000943819-26-000096
2026-11-11Filed 2026-11-13	Rider Michael JOfficer · Global General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. F2 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. F3 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. F4 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. F5 Includes 41.7624 shares of Resmed stock purchased on Oct 30, 2026 through the Resmed Employee Stock Purchase Plan. References: F2	F WithholdingResMed Common Stock · Non-derivative	498.624D	234.11	Direct	Form 4 ↗0000943819-26-000096
2026-11-11Filed 2026-11-13	Rider Michael JOfficer · Global General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. F2 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. F3 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. F4 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. F5 Includes 41.7624 shares of Resmed stock purchased on Oct 30, 2026 through the Resmed Employee Stock Purchase Plan. References: F1	F WithholdingResMed Common Stock · Non-derivative	547.469D	234.11	Direct	Form 4 ↗0000943819-26-000096
2026-11-11Filed 2026-11-13	Gill HarjitDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. References: F1	F WithholdingResMed Common Stock · Non-derivative	35.731D	234.11	Direct	Form 4 ↗0000943819-26-000098
2026-11-11Filed 2026-11-13	De Witte JanDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. References: F1	F WithholdingResMed Common Stock · Non-derivative	59.981D	234.11	Direct	Form 4 ↗0000943819-26-000100
2026-11-11Filed 2026-11-13	FARRELL PETER CDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2025. References: F1	F WithholdingResMed Common Stock · Non-derivative	169.142D	234.11	Direct	Form 4 ↗0000943819-26-000102
2026-11-11Filed 2026-11-13	Bloomer AaronOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 6/1/2026. References: F1	F WithholdingResMed Common Stock · Non-derivative	1,095.137D	234.11	Direct	Form 4 ↗0000943819-26-000104
2026-11-09Filed 2026-11-12	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year F4 Represents date options first become exercisable. Options vest 1/3 per year References: F1, F4	M Exercise / conversionResMed Common Stock Options · Derivative	4,310D	0	Direct	Form 4 ↗0000943819-26-000091
2026-11-09Filed 2026-11-12	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year F4 Represents date options first become exercisable. Options vest 1/3 per year References: F1, F3	M Exercise / conversionResMed Common Stock Options · Derivative	683D	0	Direct	Form 4 ↗0000943819-26-000091
2026-11-09Filed 2026-11-12	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year F4 Represents date options first become exercisable. Options vest 1/3 per year References: F1, F2	S Sale (market/private)ResMed Common Stock · Non-derivative	4,993D	235.3473	Direct	Form 4 ↗0000943819-26-000091
2026-11-09Filed 2026-11-12	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year F4 Represents date options first become exercisable. Options vest 1/3 per year References: F1	M Exercise / conversionResMed Common Stock · Non-derivative	4,310A	146.34	Direct	Form 4 ↗0000943819-26-000091
2026-11-09Filed 2026-11-12	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year F4 Represents date options first become exercisable. Options vest 1/3 per year References: F1	M Exercise / conversionResMed Common Stock · Non-derivative	683A	146.34	Direct	Form 4 ↗0000943819-26-000091
2026-10-23Filed 2026-10-26	Rider Michael JOfficer · Global General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025. References: F1	S Sale (market/private)ResMed Common Stock · Non-derivative	400D	255	Direct	Form 4 ↗0000943819-26-000086
2026-10-07Filed 2026-10-08	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year References: F1, F3	M Exercise / conversionResMed Common Stock Options · Derivative	4,991D	0	Direct	Form 4 ↗0000943819-26-000085
2026-10-07Filed 2026-10-08	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year References: F1, F2	S Sale (market/private)ResMed Common Stock · Non-derivative	4,991D	226.3349	Direct	Form 4 ↗0000943819-26-000085
2026-10-07Filed 2026-10-08	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year References: F1	M Exercise / conversionResMed Common Stock · Non-derivative	4,991A	146.34	Direct	Form 4 ↗0000943819-26-000085
2026-09-08Filed 2026-09-10	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $220.680 - $225.390. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year. References: F1, F3	M Exercise / conversionResMed Common Stock Options · Derivative	4,991D	0	Direct	Form 4 ↗0000943819-26-000052
2026-09-08Filed 2026-09-10	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $220.680 - $225.390. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year. References: F1, F2	S Sale (market/private)ResMed Common Stock · Non-derivative	4,991D	222.4385	Direct	Form 4 ↗0000943819-26-000052
2026-09-08Filed 2026-09-10	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $220.680 - $225.390. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year. References: F1	M Exercise / conversionResMed Common Stock · Non-derivative	4,991A	146.34	Direct	Form 4 ↗0000943819-26-000052
2026-09-02Filed 2026-09-04	FARRELL PETER CDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. References: F1	S Sale (market/private)ResMed Common Stock · Non-derivative	970D	234.73	Direct	Form 4 ↗0000943819-26-000050
2026-08-14Filed 2026-10-01	Leong JustinOfficer · Chief Product Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents performance-based restricted stock units granted on November 20, 2025. The RSUs were earned on August 14, 2026, when the compensation and leadership development committee certified that the applicable performance metrics were met. RSUs vest 1/3 each year on the anniversary of the grant. References: F1	A Award / grantResMed Common Stock · Non-derivative	6,461A	0	Direct	Form 4 ↗0000943819-26-000077
2026-08-14Filed 2026-10-01	Rider Michael JOfficer · Global General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents performance-based restricted stock units granted on November 20, 2025. The RSUs were earned on August 14, 2026, when the compensation and leadership development committee certified that the applicable performance metrics were met. RSUs vest 1/3 each year on the anniversary of the grant. References: F1	A Award / grantResMed Common Stock · Non-derivative	3,230A	0	Direct	Form 4 ↗0000943819-26-000076
2026-08-14Filed 2026-10-01	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents performance-based restricted stock units granted on November 20, 2025. The shares were earned on August 14, 2026, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. References: F1	A Award / grantResMed Common Stock · Non-derivative	13,547A	0	Direct	Form 4 ↗0000943819-26-000075
2026-08-14Filed 2026-10-01	Bloomer AaronOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents performance-based restricted stock units granted on June 1, 2026. The RSUs were earned on August 14, 2026, when the compensation and leadership development committee certified that the applicable performance metrics were met. RSUs vest 1/3 each year on the anniversary of the grant. References: F1	A Award / grantResMed Common Stock · Non-derivative	9,072A	0	Direct	Form 4 ↗0000943819-26-000073

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.